Company Info

Revolo Biotherapeutics

Drug Discovery & Development

Overview

We are on a mission to change the lives of people with autoimmune and allergic diseases by developing therapies that reset the immune system to achieve long-term disease remission. Revolo Biotherapeutics (“Revolo Bio”) has a global footprint, with headquarters in both New Orleans, LA, in the US, and London in the United Kingdom.

Our team of accomplished industry professionals has a track record of success in funding and executing drug development and commercialization plans. We are ready to revolutionize autoimmune and allergic disease treatment!

1 Contributors1 / 1

Jonathan Rigby

Chief Executive Officer

1 / 1

2 Contributions1 / 1

Immunology

Applying Revolutionary Thinking to Autoimmune and Allergic Diseases

Jonathan Rigby

Revolo Biotherapeutics

PAO-04-22-R250-66Apr 19, 2022

Rebranding

Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases

Revolo Biotherapeutics

PR-M11-20-041Mar 05, 2021

1 / 1